ATXS Logo

Astria Therapeutics, Inc. (ATXS) 

NASDAQ
Market Cap
$539.51M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
18 of 960
Rank in Industry
14 of 550

Largest Insider Buys in Sector

ATXS Stock Price History Chart

ATXS Stock Performance

About Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, …

Insider Activity of Astria Therapeutics, Inc.

Over the last 12 months, insiders at Astria Therapeutics, Inc. have bought $30M and sold $247,303 worth of Astria Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Astria Therapeutics, Inc. have bought $12.9M and sold $247,303 worth of stock each year.

Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (director) — $622.58M.

The last purchase of 2,481,350 shares for transaction amount of $30M was made by PERCEPTIVE ADVISORS LLC (director) on 2024‑02‑01.

List of Insider Buy and Sell Transactions, Astria Therapeutics, Inc.

2024-04-01SaleChief Medical Officer
10,000
0.0183%
$13.59$135,939-22.28%
2024-02-01Purchasedirector
2.48M
5.6893%
$12.09$30M-17.48%
2024-01-29SaleChief Medical Officer
9,200
0.0208%
$11.15$102,552-6.16%
2024-01-26SaleChief Medical Officer
800
0.0022%
$11.02$8,812+3.56%
2023-12-21Purchasedirector
740,000
2.0257%
$6.20$4.59M+76.96%
2023-10-16Purchasedirector
1.07M
3.9128%
$6.51$7M+53.54%
2022-12-19Purchasedirector
908,265
6.1619%
$11.01$10M-10.50%
2021-11-19PurchaseChief Commercial Officer
100
0.0008%
$6.70$670-6.97%
2015-06-30Purchase10 percent owner
391,090
2.5125%
$12.00$4.69M-41.69%
2015-06-30Purchase
376,695
2.4201%
$12.00$4.52M-41.69%
2015-06-30Purchase10 percent owner
376,695
2.4201%
$12.00$4.52M-41.69%
2015-06-30Purchase10 percent owner
223,439
1.4355%
$12.00$2.68M-41.69%
2015-06-30Purchase
223,439
1.4355%
$12.00$2.68M-41.69%
2015-06-30Purchasedirector
258,776
1.6625%
$12.00$3.11M-41.69%

Insider Historical Profitability

<0.0001%
PERCEPTIVE ADVISORS LLCdirector
4873721
8.6361%
$9.5640<0.0001%
SVLSF V, LLC10 percent owner
2798528
4.9589%
$9.5610
GALAKATOS NICHOLAS
2752488
4.8773%
$9.5610
Clarus Lifesciences II, L.P.10 percent owner
2752488
4.8773%
$9.5610
MedImmune Ventures, Inc.10 percent owner
1632652
2.893%
$9.5610

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$91.25M11.816.49M+61.97%+$34.91M0.06
Tcg Crossover Management Llc$74.3M9.615.28MNew+$74.3M0.12
RA Capital Management, L.P.$62.12M8.044.41MNew+$62.12M0.06
Fidelity Investments$60.79M7.874.32M-10.07%-$6.81M<0.01
Vr Adviser Llc$50.79M6.573.61M+11.87%+$5.39M2.47
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.